Provided by Tiger Fintech (Singapore) Pte. Ltd.

Intellia Therapeutics

9.85
+0.48505.18%
Volume:1.94M
Turnover:18.32M
Market Cap:1.02B
PE:-1.88
High:9.98
Open:9.00
Low:8.88
Close:9.37
Loading ...

NTLA LAWSUIT ALERT: Levi & Korsinsky LLP Notifies Intellia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

TIPRANKS
·
12 Feb

Intellia Therapeutics Inc. (NTLA): Among Cathie Wood’s Top Stock Picks for 2025

Insider Monkey
·
07 Feb

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
05 Feb

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
05 Feb

Intellia Therapeutics Shares Fall After Morgan Stanley Downgrade

MT Newswires Live
·
28 Jan

Update: Morgan Stanley Downgrades Intellia Therapeutics to Equal Weight From Overweight, Cuts Price Target to $11 From $56

MT Newswires Live
·
28 Jan

Morgan Stanley Downgrades Intellia Therapeutics to Equal Weight From Overweight, $56 Price Target

MT Newswires Live
·
27 Jan

Intellia Therapeutics Cut to Equal-Weight From Overweight by Morgan Stanley

Dow Jones
·
27 Jan

Intellia Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley

TIPRANKS
·
27 Jan

NTLA Begins Dosing in Pivotal Study on Hereditary Angioedema Candidate

Zacks
·
23 Jan

Intellia Doses First Patient in Phase 3 Trial of Potential Treatment for Hereditary Angioedema

MT Newswires Live
·
22 Jan

Intellia Therapeutics announces first patient dosed in Phase 3 NTLA-2002

TIPRANKS
·
22 Jan

Intellia Therapeutics Announces First Patient Dosed in the Haelo Phase 3 Study of Ntla-2002, an Investigational in Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema

THOMSON REUTERS
·
22 Jan

Intellia Therapeutics Inc - Expects to Complete Enrollment in Phase 3 Study by H2 2025

THOMSON REUTERS
·
22 Jan

Intellia Therapeutics Inc: Expects to Submit a Bla in 2026 to Support Plans for a U.S. Launch in 2027

THOMSON REUTERS
·
22 Jan

Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema

GlobeNewswire
·
22 Jan